Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from July 23, 2025

Near target Published before the outcome was known, scored automatically when the window closed on October 21, 2025 — +8.4% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$76.15 – $79.05Entry zone — fair-value band

$80.13Published — price the day we called it

$88.90Target — the price the thesis aimed for

$90.23Peak — highest point inside the window, not a realized return

$86.88Window close — end-of-window price, context only

What happened

Near target

Came within reach: 97% of the predicted growth at its peak, just short of the target.

At window close

+8.4%

realized, from the publication price to the last close inside the window

Peak gain

+12.6%

peak, from the publication price — not a realized return

S&P 500, same window

+6.1%

SPY over the identical days, dividend-adjusted

Window close

$86.88

last close inside the window, ended October 21, 2025

Peak price

$90.23

peak on October 2, 2025 — not a realized return

Days to target

—

The thesis — published July 23, 2025

Predicted growth

+13%

over the measurement window

Target price

$88.90

the price the thesis aimed for

Entry zone

$76.15 – $79.05

the fair-value band we waited for

Price at publication

$80.13

published July 23, 2025

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The stock is priced at about 14 times what analysts think it will earn in 2025. New cancer and immune system medicines could replace revenue lost when Keytruda faces copycats in 2028. Lots more people are buying the shares than selling, even with worries about tariffs. Key study results and a European drug decision expected in the next few months could lift the price toward $95.

Primary drivers

Key trial results for a head and neck treatment and EU view on cough drug due in Q3.
Strong buying trend signals fresh demand, pointing to higher prices ahead.
Shares trade at 14 times 2025 profit versus rivals at 17, leaving room to re-rate.
Tariff debates push investors toward big drug firms like Merck for safety.

How it played out

MRK: price crossed target, growth fell just short

Lyra published MRK at 80.13 on 2025-07-23 with 13% expected growth. The thesis pointed to trial results for a head and neck treatment, a European view on a cough drug, strong buying demand, a 14 times 2025 profit valuation versus rivals at 17, and investor demand for large drug firms during tariff debates.

Inside the window, MRK peaked at 90.23 on 2025-10-02. That was above the 88.90 target, but the recorded peak gain was 12.6%, just under the published 13% expectation. It ended at 86.88 on 2025-10-21. The thesis mostly played out, but not cleanly.

What happened during the window

On 2025-07-29, Merck reported second-quarter revenue of $15.81 billion and announced a $3 billion cost-cutting plan. The same report said adjusted EPS was $2.13.

Merck will lay off employees and shed some real estate to cut $3 billion in costs

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals